OlgaFrankfurtMD

Hematology • Chicago, IL

Assistant Professor in Medicine-Hematology/Oncology, Northwestern University Medical School

Join to view full profile

Dr. Frankfurt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frankfurt's full profile

Already have an account?

Office
675 N Saint Clair St
Suite 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
Rush University Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2022 - 2026
IL State Medical License 2002 - 2026

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Start of enrollment: 2005 Sep 26
Completed
Phase 2
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Start of enrollment: 2015 Mar 11
Terminated
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Leukemia Start of enrollment: 2014 Mar 01
Completed
Phase 1
Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota
Blood Advances. 2023-12-26
7 citations
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Chenyu Lin, Aurelie Schwarzbach, Jaime Sanz, Pau Montesinos, Patrick Stiff
Transplantation and Cellular Therapy. 2023-05-01
46 citations
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Stéphane de Botton, Pau Montesinos, Andre C Schuh, Cristina Papayannidis, Paresh Vyas
Blood. 2023-01-12

Journal Articles

Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood

Abstracts/Posters

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...
Olga Frankfurt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
Olga Frankfurt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Apellis Announces U.S. FDA Approval of Empaveli (Pegcetacoplan) for Adults with Paroxysmal Nocturnal HemoglobinuriaMay 20th, 2021
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)May 14th, 2021
Midday Fix: Campaign 2 Save Lives – Event to Help Those Battling LeukemiaMay 15th, 2018
Join now to see all